{"name":"Grifols Biologicals, LLC","slug":"grifols-biologicals-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fibrin Sealant (FS) Grifols","genericName":"Fibrin Sealant (FS) Grifols","slug":"fibrin-sealant-fs-grifols","indication":"Hemostasis and tissue adhesion during surgical procedures","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"IGIV3I Grifols 10%","genericName":"IGIV3I Grifols 10%","slug":"igiv3i-grifols-10","indication":"Primary immunodeficiency disorders","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Alphanate SD/HT","genericName":"Alphanate SD/HT","slug":"alphanate-sd-ht","indication":"Hemophilia A (congenital Factor VIII deficiency) — treatment and prevention of bleeding episodes","status":"marketed"}]}],"pipeline":[{"name":"Fibrin Sealant (FS) Grifols","genericName":"Fibrin Sealant (FS) Grifols","slug":"fibrin-sealant-fs-grifols","phase":"phase_3","mechanism":"Fibrin sealant is a topical hemostatic agent that forms a fibrin clot by combining fibrinogen and thrombin to achieve rapid hemostasis at surgical sites.","indications":["Hemostasis and tissue adhesion during surgical procedures","Control of bleeding in general surgery, cardiovascular surgery, and other surgical applications"],"catalyst":""},{"name":"IGIV3I Grifols 10%","genericName":"IGIV3I Grifols 10%","slug":"igiv3i-grifols-10","phase":"phase_3","mechanism":"IGIV3I is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune responses and provide immunoprotection.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"Alphanate SD/HT","genericName":"Alphanate SD/HT","slug":"alphanate-sd-ht","phase":"marketed","mechanism":"Alphanate SD/HT is a plasma-derived Factor VIII concentrate that replaces deficient clotting factor VIII to restore hemostasis in patients with hemophilia A.","indications":["Hemophilia A (congenital Factor VIII deficiency) — treatment and prevention of bleeding episodes","Perioperative management in hemophilia A patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQYzZ1WkFVendNaW5NUzZvWGdla3MtaENFd2pfWGRSWFZlSGZad21kX1ZQZjdHQ2tZQldrQTBOX0hkcWZ4WnczZlhJQjJPOVlEaWRHSkZTRm5VS0VjSHdhM05rZE50SXJ6SHlWN0ZPLTdwZGw5Z2k1NVYtYXJBOVZjVVlrXzctaTBGYk1Z?oc=5","date":"2026-04-05","type":"pipeline","source":"IndexBox","summary":"Immunome CSO Sells Shares: Transaction Details & Company Snapshot - News and Statistics - IndexBox","headline":"Immunome CSO Sells Shares: Transaction Details & Company Snapshot - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOdmJtTy1PVXBHWGpWQ0dlM1otWU01LWJUZ0MtM0ZpRklNbW44d1BBdTR4WlRvdXViT1NTNW5VTlFKSXZoRTJSYkJadHVoTFh0R0lNQnV2VEtaUnptVmxYeWhkNU0tUldGRHdxSUh6YWd2ZWdWMzBrbVR6QVgwd0NlRV91MGY4aUdwR1lpMXJfcnJLQnp1eUF4UW5LaDBzcHdoZWxOdnlKeVE4M3ZpZ3k2czdmTjh3UUxnX2FXZ2dGNm5YTzJJVEtPUTNuZUxQLWRLWmtOTUpKMklFd29GU25xUVNWMTNGdkljeTJVdEJvdi1TTTBXWDFTWW0tRi1hNkFEbm56dUp5ZTV3Mm96bmFXZ1dFVWZ2Qk12UVpZR09B?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNNXBUV0xERXFESWN2Y0Y5ckVqM2hLemxRakFFVnZnTW1ESTRfLVZiRUgxb2lxUlo1VzNDU1REbnRpWVdNak1scmh0bldHR2hzd0F0TjdHeldRcE52R2syXzVmbGQ5RnVfVUVteTlZV3JJZWNreTNUS0ZPd2hWajZNbVFsMTRTc1ZTYTYxa1pidE5BOGRwLUFZU3IyTVNzSkE?oc=5","date":"2026-01-15","type":"pipeline","source":"The Business Journals","summary":"Prime land near pharma giants sold for $1 million - The Business Journals","headline":"Prime land near pharma giants sold for $1 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQc1c1d25oR2hwN3VOY2JmOHlPOE1ramlTdENfWlNqSzhhblNSZHpzbngxcXJlUE44WGFHeXd4UHBLVzh6d2xORHUxZ3U4VFhzRmI0aFo0d2ZhZl9QRHQ5ejhGV05wVG5TeFJpNk5rUWlaQi1QOXNPNnFDdUdGalFiVThDNVZjX01nQ1l6TUxncHAwclVfUHk3Njc5aGhhSy0xS1pucXNqaEFxS25mZWg4MV8tNzg3RHJOM2M0bHh4NFFMZEFrQl9nZjNnRW9ZYnM1U193QVJOMnVRLXptbnJILVRZcjZVOEx6SzMw?oc=5","date":"2025-05-30","type":"pipeline","source":"Reuters","summary":"US court proceeds with Grifols defamation case against Gotham City, but narrows scope - Reuters","headline":"US court proceeds with Grifols defamation case against Gotham City, but narrows scope","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaENlQ1VENWItVXRWTmpwZ251dW1QT0U2ZkVHTUdITlRWWl9TeDZta19JSl9KT2R0d29xTUM5dkpSUFdyZ1gyNFByTktCTHVWMTVaZUNJYkM3emZhTTlfZ0oxMlZneFI1ZGl2T0U5V1EteWZKUnFfUDVNd3FaWjVCX1RRMW10MG51Z1RmOWU5VHFyLVdqeXVWX19UWUpUSnVYT2dEcHphYnlvTmxabFlfaGwtekRkTU1qdHpF?oc=5","date":"2025-01-14","type":"pipeline","source":"Fierce Biotech","summary":"Grifols garners $21M grant from Michael J. Fox Foundation to hunt for early Parkinson's disease biomarkers - Fierce Biotech","headline":"Grifols garners $21M grant from Michael J. Fox Foundation to hunt for early Parkinson's disease biomarkers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQUDJmbHlUeUNqTHJ3R3lPZ0ZLQjJhSFkyRHY0M0h5cEdOU3lyZDJPaHFNUkJmV0hNTEFrR3hUaG9xU1dlam5ETnRrYXVtZFBuYWc1Nm1YWEZOMGFzZjdzd2NHWGpaRVZBTTI2b3VVeEhUekxReEhUcktzQXJBMjhKRFZ5dnRwS3dLMjZ5azRYbkhpcG44aUlQYnM2S1Ricm1tQno1TDVaQWYtQzl1X1F5bWdEajUzeUJpcFJpTXUwYmFDWXM?oc=5","date":"2024-11-20","type":"pipeline","source":"Fierce Pharma","summary":"Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer - Fierce Pharma","headline":"Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOeVNnMFpvbDBCY2R0UEROU0ZmNnEtekczcTUxQVgzSFBhMkxpaGxPQUEwREk4ZjN0NDlhc2d2c2JFdU5jcDFVaHdPcnFsS3RIelVOZW9veVZLT2FyLVItam5PUTB3bUJIUWY1ZEI3aE5zMy1nX0ExN1FJQ3A0bGhlOExWZ0VaRjBZM3FyS3dmZ0ZkbURJ?oc=5","date":"2024-05-24","type":"trial","source":"drugdiscoverytrends.com","summary":"Cencora data breach exposes patient data at top pharma firms - drugdiscoverytrends.com","headline":"Cencora data breach exposes patient data at top pharma firms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOalVfazF1enc3RVA1YzgzcWhKX0xNdi1STVI2eVRoQWVSMS1OU194NVVKNjI4NGgxcDBvWEFwTnZySWN6cGpaT2NFZjZKemdCSjhLbzFIa1lDamZfNzdxTE16T2g3azhFcFJkemkzQmtibUxteXN2aVpZdTBjcVlJY1lJMlV6Tl9mSlJqdm1hWkU4aW5sY2ZaYnhvLXBUVElfM2Q0eGJLLWFoVUZqX005STRn?oc=5","date":"2023-02-15","type":"pipeline","source":"Fierce Pharma","summary":"Grifols jumps pharma's 2023 layoff queue with plans to scrap 2,300 jobs, primarily in the US - Fierce Pharma","headline":"Grifols jumps pharma's 2023 layoff queue with plans to scrap 2,300 jobs, primarily in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBTV1VodWM3a19jcDQ4U1dyZENfbUNLSkQ3c0dnVHV4dGJZMVJ0bkY5a1h3ck9FTHlZZDNWUGlMN2pxYkJsV0JmZ2xualRRblRoVEpvOTB0d3NSUHpXWGlhdFVpbFBrQ3BfbmpXVVhjRnBEeDg?oc=5","date":"2023-02-08","type":"pipeline","source":"Gibson Dunn","summary":"2022 Year-End False Claims Act Update - Gibson Dunn","headline":"2022 Year-End False Claims Act Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNMnNhTTNmT3ZnMnlCV1F1UWlMc2xGTldFTFJaN3RNUmhmVUg4cmlwcU9TUU5qcXJ2cHg4dm5FbVdfcUpnMThRWHd0RkU2UGlfd3AzeUtWUHlPd2RwMzRpWUZ0RExKaHF2VTh5Rlpuc09tNllsS1F6Zjg5Q3RTS0pfbm50NHlMSHRfc1JwSVVSbksxdw?oc=5","date":"2017-01-12","type":"pipeline","source":"Drug Delivery Business","summary":"Grifols pays $51m for minority stake in Access Biologicals - Drug Delivery Business","headline":"Grifols pays $51m for minority stake in Access Biologicals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOWTVhbUlIc3RTZXAxbmNtN1EyMnd2LTN6VklTQ1l1ZjFfSFBFRWlXX0RvYlpONUtHeHdaWXBGTHpzdGNSb1UyNWc0TDhZV2E2RTMtVkhHdjlERXBENlV5bW5YS3pBempXSTc2T3dITU1sNGtSbV83UzIwTHRBSlEtMDhfb3o?oc=5","date":"2017-01-12","type":"pipeline","source":"MassDevice","summary":"Grifols pays $51m for minority stake in Access Biologicals - MassDevice","headline":"Grifols pays $51m for minority stake in Access Biologicals","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}